Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
Authors:
Top Cited Papers
Open Access
- 4 May 2023
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 29 (5) , 1180-1190
Abstract
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 nodules and severe itch uncontrolled with topical therapies. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13. Patients were randomized 1:1 to 300 mg dupilumab or placebo subcutaneously every 2 weeks for 24 weeks. The primary endpoint was pruritus improvement, measured by proportion of patients with a ≥4-point reduction in Worst Itch Numeric Rating Scale (WI-NRS) from baseline at week 24 (PRIME) or week 12 (PRIME2). Key secondary endpoints included nodule number reduction to ≤5 at week 24. PRIME and PRIME2 enrolled 151 and 160 patients, respectively. Both trials met all the pre-specified primary and key secondary endpoints. A ≥4-point WI-NRS reduction at week 24 in the dupilumab and placebo arms was achieved by 60.0% and 18.4% of patients, respectively, in PRIME (95% confidence interval (CI), 27.8–57.7 for the difference, P < 0.001) and at week 12 by 37.2% and 22.0% of patients, respectively, in PRIME2 (95% CI, 2.3–31.2; P = 0.022). Dupilumab demonstrated clinically meaningful and statistically significant improvements in itch and skin lesions versus placebo in PN. Safety was consistent with the known dupilumab safety profile.ClinicalTrials.gov identifiers: NCT04183335 and NCT04202679.Keywords
Funding Information
- Sanofi
- Regeneron Pharmaceuticals
This publication has 58 references indexed in Scilit:
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences, 2014
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genesProceedings of the National Academy of Sciences, 2014
- Prurigo as a symptom of atopic and non‐atopic diseases: aetiological survey in a consecutive cohort of 108 patientsJournal of the European Academy of Dermatology and Venereology, 2012
- Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularisBritish Journal of Dermatology, 2011
- Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathyBritish Journal of Dermatology, 2011
- Translating the Science of Quality of Life into Practice: What Do Dermatology Life Quality Index Scores Mean?Journal of Investigative Dermatology, 2005
- International experiences with the Hospital Anxiety and Depression Scale-A review of validation data and clinical resultsJournal of Psychosomatic Research, 1997
- Prurigo nodularis Consists of Two Distinct Forms: Early-Onset Atopic and Late-Onset Non-AtopicDermatology, 1995
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983